IQVIA Holdings (IQV) has put artificial intelligence at the center of its story by launching IQVIA.ai in collaboration with NVIDIA. The goal is to embed agentic AI directly into life sciences workflows across clinical, commercial and real-world applications.

Despite the IQVIA.ai launch and recent broker upgrades, the share price is US$163.85 after a 1 day share price return of a 3.28% decline and a 90 day share price return of a 27.79% decline, while the 1 year total shareholder return of a 7.63% decline points to fading momentum over a longer horizon.

If AI in healthcare has your attention, it is worth widening your watchlist with our screener of 34 healthcare AI stocks

With IQVIA.ai gaining attention and IQVIA shares down over the past year, the stock now trades at a steep discount to analyst targets and intrinsic estimates. Is this weakness a chance to buy, or is the market already pricing in future growth?

Most Popular Narrative: 34.5% Undervalued

IQVIA Holdings' most followed narrative sets a fair value of $250 per share, well above the last close at $163.85, and ties that gap directly to future earnings power and AI driven efficiency.

Accelerated adoption of AI driven analytics and data solutions, supported by strong client demand and high profile industry partnerships like NVIDIA, positions IQVIA for improved operational efficiency, faster project execution, and differentiation, which should support future revenue growth and eventual margin expansion as AI capabilities scale.

Curious what earnings trajectory and margin profile are baked into that fair value, and how much multiple compression is already assumed? The full narrative spells it out in detail.

Result: Fair Value of $250 (UNDERVALUED)

However, ongoing pricing pressure in the CRO market and IQVIA’s relatively high leverage could quickly challenge the earnings and valuation assumptions behind that 34.5% “undervalued” label.

Next Steps

With sentiment clearly split between opportunity and concern, now is the time to look under the hood yourself and move ahead with conviction by weighing 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If IQVIA has sharpened your focus, do not stop here. Broaden your opportunity set with a few targeted stock ideas pulled directly from the Simply Wall Street Screener.

• Target reliable income by reviewing companies in the 12 dividend fortresses that may help anchor your portfolio with steady cash flows.
• Prioritise resilience by checking out businesses in the 67 resilient stocks with low risk scores that score well on financial strength and risk metrics.
• Hunt for future standouts by scanning the screener containing 26 high quality undiscovered gems that the crowd may not be watching yet but still show solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.